In the latest quarter, 5 analysts provided ratings for Capricor Therapeutics (NASDAQ:CAPR), showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $23.0, along with a high estimate of $40.00 and a low estimate of $8.00. Surpassing the previous average price target of $22.80, the current average has increased by 0.88%. Diving…